The pharmaceutical care and analysis of one patient with lung cancer treated with chemotherapy combined with recombinant human endostatin
XIE Ting-ting
WANG Dong-xiao
Abstract：One 58-year-male patient had a history of hypertension and diabetes mellitus, and was admitted to the hospital for 2 months after the diagnosis of pulmonary squamous cell carcinoma. The patient's blood routine and blood biochemistry were normal, the patient was given gemcitabine (1.8 g, d1, d8) + recombinant human endostatin (30 mg, d1-7) and carboplatin (0.4 g,d1) including liver-protecting, stomach-protecting, antiemetic and other symptomatic treatment. According to guidelines, clinical pharmacists communicated with the doctor actively, and suggested paying attention to the dose and treatment course of ecombinant human endostatin, and close monitoring of the patient's blood routine, biochemical indexes during the chemotherapy and medication education for patients. During the period of treatment, the patient showed no symptoms of discomfort. The patient was ordered to review and follow up regularly after discharge.
Keywords：Lung adenocarcinomaRecombinant human endostatinOff-label usePharmaceutical care
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 343-346 )